TI
OKUR

Trexquant Investment’s OnKure Therapeutics OKUR Stock Holding History

Trexquant Investment’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,076
Closed -$158K – 1869
2023
Q3 		$158K Buy
+2,076
New +$141K ﹤0.01% 1368

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Trexquant Investment's OKUR Position: Q4 2023 in Review

Trexquant Investment sold out of OnKure Therapeutics (OKUR) in Q4 2023, closing a stake of 2,076 shares — an estimated $158K sold.

Trexquant Investment first reported a position in OKUR in Q3 2023 and held it in 1 quarter. The position peaked at $158K in Q3 2023. 68 funds tracked by Wall St. Rank hold OKUR as of Q4 2023.

  • Trexquant Investment reported no remaining OnKure Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Trexquant Investment sold 2,076 OnKure Therapeutics shares in Q4 2023, an estimated $158K.
  • Trexquant Investment first reported a position in OnKure Therapeutics in Q3 2023 and held it in 1 quarter.
  • Trexquant Investment's OnKure Therapeutics position peaked at $158K in Q3 2023.
  • 68 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q4 2023.

Based on Trexquant Investment's 13F filing for Q4 2023, filed 9 Feb 2024.